Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Table 2 Outcomes included in the summary of results.

From: The efficacy of duloxetine: A comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials

17-item Hamilton Rating Scale for Depression (HAMD17)

   Total score [24]

   Core subscale (items 1, 2, 3, 7, 8) (not published)

   Maier subscale (items 1, 2, 7, 8, 9, 10) [25]

   Anxiety/Somatization subscale (items 10, 11, 12, 13, 15, 17) [26]

   Retardation subscale (items 1, 7, 8, 14) [27]

   Sleep subscale (items 4, 5, 6) [27]

Montgomery-Asberg Depression Rating scale [28]

Hamilton Anxiety Rating Scale total score [29]

Clinical Global Impression of Severity [26]

Patient Global Impression of Improvement [26]

Visual Analog Scale for pain [30]

   Overall pain severity

   Headaches

   Back pain

   Shoulder pain

   Time in pain while awake

   Interference with daily activities

Somatic Symptom Inventory [31]

   26 Item total score

   28 Item total score (includes 2 additional questions on painful physical symptoms)

Quality of Life in Depression Scale total score [32]